We’re looking forward to connecting with you at the 30th Annual San Diego Heart Failure Symposium! Join us at the Saturday Breakfast Session to hear from Drs. Budoff and Greenberg on “Harnessing SGLT Inhibition in the Treatment of Heart Failure.” #SDHF2024 #HeartFailure
Lexicon Pharmaceuticals, Inc.
Pharmaceutical Manufacturing
The Woodlands, TX 19,677 followers
At Lexicon, We Pioneer Medicines that Transform Patients' Lives
About us
Corporate Overview Lexicon Pharmaceuticals is a biopharmaceutical company that has harnessed the power of genetics for drug discovery. Our research team has generated a pipeline of novel drug candidates in clinical development across a broad range of indications. The Genome: Our Source of Discovery We have applied gene knockout technology to thousands of potential drug targets encoded in the human genome. Our scientists have gained a thorough understanding of target biology and identified new points of intervention for future therapies. We have integrated a series of recombinant DNA and chemistry technologies into a systematic drug discovery and development process. Our unique knowledge of targets from the human genome has allowed us to better evaluate and advance novel drug candidates with great promise for patients. A Diverse Pipeline of Targeted Therapies Our genomics-based approach to drug discovery has enabled our scientists to select drug targets across a broad range of indications with high unmet medical need. All of our drug candidates are new molecular entities discovered internally by our dedicated drug discovery teams and designed to affect particular points on a genetically-defined pathway that can be used to fight a disease process. We have advanced new therapies across a wide spectrum of human disease, from conditions affecting millions of people, such as diabetes, to carcinoid syndrome, an orphan cancer indication with few treatment options.
- Website
-
http://www.lexpharma.com/
External link for Lexicon Pharmaceuticals, Inc.
- Industry
- Pharmaceutical Manufacturing
- Company size
- 51-200 employees
- Headquarters
- The Woodlands, TX
- Type
- Public Company
- Founded
- 1995
- Specialties
- biopharma, knockout, novel drug, innovation, disease, and pharmaceutical
Locations
-
Primary
8800 Technology Forest
The Woodlands, TX 77381, US
-
-
110 Allen Rd
Basking Ridge, NJ 07920, US
Employees at Lexicon Pharmaceuticals, Inc.
Updates
-
Lexicon Pharmaceuticals Receives December 20, 2024 PDUFA Goal Date for Sotagliflozin Type 1 Diabetes NDA Resubmission. To view the full press release, visit our website: bit.ly/3LLc2uF #LexiconNews #T1D #Type1Diabetes
-
-
Tom Garner, our Chief Commercial Officer, has a great perspective on progress in education and treatment related to heart failure, particularly by the American Association of Heart Failure Nurses. #Lexicon #HeartFailure #Teamwork #AAHFN
Heart disease remains a significant and growing health concern in the U.S. While the progress in education and advancing new treatments is promising, we should not lose sight of the important contributions from Heart Failure nurses on the front lines of care. Their ongoing dedication and expertise are vital in improving patient outcomes and deserve recognition. #Lexicon #Heartfailure #teamwork #AAHFN #cardiology
-
New Published Data Highlights Potential Cost-Savings of INPEFA® (Sotagliflozin) for Heart Failure. To view the full press release, visit our website: bit.ly/3y8Tm4u #LexiconNews #HeartFailure
-
-
We are pleased to welcome Mike Exton, Ph.D. as our new chief executive officer! #Lexicon
-
-
Lexicon Board of Directors Appoints Mike Exton, Ph.D. as New Chief Executive Officer and Director. To view the full press release, visit our website: bit.ly/4cupezv #LexiconNews
-
-
We’re headed to Nashville for the 2024 American Association of Nurse Practitioners (AANP) meeting. Stop by Booth #1248 to learn more about an FDA-approved product for heart failure. #HeartFailure #AANP24
-
We’re in Orlando for the 84th annual ADA Scientific Sessions! Join us tomorrow at 12:30 PM ET in the Poster Hall for a presentation on a sub-study of RELIEF-DPN 1. Learn more about our participation at #ADASciSessions: bit.ly/3KKuAKS #LexiconNews #DPNP
-
-
Lexicon Pharmaceuticals Resubmits Sotagliflozin NDA for Type 1 Diabetes. To view the full press release, visit our website: bit.ly/4bdnVUj #LexiconNews #T1D #Type1Diabetes
-
-
Data From Lexicon’s RELIEF-DPN 1 Phase 2 Study of LX9211 Published Today in Diabetes Care, a Peer-Reviewed Journal of the American Diabetes Association. To view the full press release, visit our website: bit.ly/3xfgiyT #LexiconNews #ADASciSessions #DiabetesCare #DPNP
-
Affiliated pages
Similar pages
Browse jobs
Stock
LXRX
NASDAQ
20 minutes delay
$2.13
-0.1 (-4.484%)
- Open
- 2.25
- Low
- 2.09
- High
- 2.26
Data from Refinitiv
See more info on